Heidelberg Pharma AG
Clinical-stage biopharma developing Amanitin-based ADCs for targeted cancer therapies.
HPHA | F
Overview
Corporate Details
- ISIN(s):
- DE000A11QVV0
- LEI:
- 391200E09XYBYITR1W32
- Country:
- Germany
- Address:
- Gregor-Mendel-Str. 22, 68526 Ladenburg
- Sector:
- Manufacturing
Description
Heidelberg Pharma AG is a clinical-stage biopharmaceutical company specializing in the development of targeted cancer therapies. The company's core focus is its proprietary Antibody-Drug Conjugate (ADC) technology platform, which utilizes the toxin Amanitin. This platform, known as Antibody Targeted Amanitin Conjugates (ATACs®), is designed to deliver the highly potent Amanitin payload directly to tumor cells. Heidelberg Pharma is the first company to advance Amanitin into clinical development for cancer treatment. Its lead candidate, HDP-101, is in clinical trials for patients with multiple myeloma. The company leverages its ADC expertise to create novel medicines for oncology.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-03-21 00:00 |
Annual financial report 2023/2024
|
English | 3.7 MB | ||
| 2025-03-14 07:30 |
Heidelberg Pharma Amends Royalty Financing with HealthCare Royalty
|
English | 13.1 KB | ||
| 2025-03-13 00:31 |
Heidelberg Pharma Amends Royalty Financing with HealthCare Royalty
|
English | 12.5 KB | ||
| 2025-01-24 10:55 | English | 5.6 KB | |||
| 2025-01-23 10:55 | English | 5.6 KB | |||
| 2025-01-23 00:00 |
Hinweis auf Konzernabschluss vom 01.12.2023 bis zum 30.11.2024
|
German | 5.8 KB | ||
| 2025-01-23 00:00 |
Hinweis auf Halbjahresfinanzbericht vom 01.12.2024 bis zum 31.05.2025
|
German | 5.8 KB | ||
| 2025-01-23 00:00 |
Hinweis auf Jahresfinanzbericht vom 01.12.2023 bis zum 30.11.2024
|
German | 5.8 KB | ||
| 2025-01-14 08:17 |
Heidelberg Pharma Progresses into Cohort 7 in a Phase I/IIa Study with BCMA ATA…
|
English | 12.8 KB | ||
| 2025-01-13 08:17 |
Heidelberg Pharma Progresses into Cohort 7 in a Phase I/IIa Study with BCMA ATA…
|
English | 12.8 KB | ||
| 2024-12-05 00:00 |
§§ 264 Abs. 3, 264b HGB zum Geschäftsjahr vom 01.12.2023 bis zum 30.11.2024
|
German | 5.1 KB | ||
| 2024-10-24 11:03 |
Heidelberg Pharma to Participate in Leading Scientific and Financial Conference…
|
English | 18.0 KB | ||
| 2024-10-10 07:06 |
Heidelberg Pharma AG: Interim Management Statement on the First Nine Months of …
|
English | 32.4 KB | ||
| 2024-10-10 00:00 |
Quartalsfinanzbericht
|
German | 72.9 KB | ||
| 2024-10-10 00:00 |
Q3 statement / Q3 financial report 2023/2024
|
English | 279.6 KB |
Automate Your Workflow. Get a real-time feed of all Heidelberg Pharma AG filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Heidelberg Pharma AG
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Heidelberg Pharma AG via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2022-03-16 | WAOW entrepreneurship GmbH | Close relation | Buy | None | 494,208.00 EUR |
| 2022-03-16 | Beretti, Giulio | Other | Buy | None | 4,025.00 EUR |
| 2022-02-22 | MH-LT-Investments GmbH | Close relation | Other | None | N/A |
| 2022-02-18 | Riedel, Oliver | Board | Buy | None | 16,122.00 EUR |
| 2022-02-18 | Riedel, Oliver | Board | Buy | None | 9,555.00 EUR |
| 2022-02-17 | Weng, Rüdiger K. | Board | Buy | None | 14,500.00 EUR |
| 2021-07-29 | Schmidt-Brand, Dr. Jan | Board | Other | None | N/A |
Peer Companies
